Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behcet Disease.

Next Previous
X
Search
Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behcet Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Behcet's syndrome; Oral ulcer
  • Focus Therapeutic Use
  • Sponsors Amgen; Celgene Corporation

    • Most Recent Events

    • 06 Jun 2020 Results of pooled analysis from RELIEF and NCT00866359 assessing efficacy of Apremilast for the Treatment of Genital Ulcers Associated with Active Behcet's-syndrome, presented at the 21st Annual Congress of the European League Against Rheumatism
    • 15 Apr 2015 According to Celgene Corporation media release, based on the results of this trial, company has filed with regulatory authorities in Turkey.
    • 15 Apr 2015 Results published in The New England Journal of Medicine, as per Celgene Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top